Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Zynex, enCore, and TFI and Encourages Investors to Contact the Firm GlobeNewswire May 08, 2025 NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class […]

Knight Therapeutics Reports First Quarter 2025 Results GlobeNewswire May 08, 2025 MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2025. All currency amounts are in thousands except for share and

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress(TM) MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution GlobeNewswire May 08, 2025 GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates GlobeNewswire May 08, 2025 CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Geron, Digimarc, XPLR, and Fluence and Encourages Investors to Contact the Firm GlobeNewswire May 08, 2025 NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire May 08, 2025 Awaiting FDA action on YUTREPIA(TM) NDA with a PDUFA goal date of May 24, 2025 District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment Fully enrolled Cohort A of ASCENT study in patients with PH-ILD Further

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress GlobeNewswire May 08, 2025 On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 GlobeNewswire May 08, 2025 WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic

Dogwood Therapeutics Announces First Quarter 2025 Financial Results GlobeNewswire May 08, 2025 – Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron(R) Chemotherapy Induced Neuropathic Pain Phase 2b Study – – Halneuron(R) Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 – – Cash on hand of $17.5M

NEXTERA ALERT: Bragar Eagel & Squire, P.C. is Investigating NextEra Energy, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire May 08, 2025 NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against NextEra Energy,